Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

View All Documentation

B1532

Sigma-Aldrich

Resorufin benzyl ether

CYP450 substrate, ≥98% (TLC), powder

Sinónimos:

7-Benzyloxy-3H-phenoxazin-3-one, 7-Benzyloxyresorufin, O7-Benzylresorufin

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C19H13NO3
Número de CAS:
87687-02-3
Peso molecular:
303.31
MDL number:
MFCD00171613
UNSPSC Code:
12352204
PubChem Substance ID:
24891597
NACRES:
NA.32

product name

Resorufin benzyl ether, CYP450 substrate

Quality Level

200

assay

≥98% (TLC)

form

powder

solubility

chloroform: 9.80-10.20 mg/mL, clear, orange

storage temp.

2-8°C

SMILES string

O=C1C=CC2=Nc3ccc(OCc4ccccc4)cc3OC2=C1

InChI

1S/C19H13NO3/c21-14-6-8-16-18(10-14)23-19-11-15(7-9-17(19)20-16)22-12-13-4-2-1-3-5-13/h1-11H,12H2

InChI key

XNZRYTITWLGTJS-UHFFFAOYSA-N

Substrates

Fluorimetric substrate for cytochrome P450-linked enzymes.

pictograms

Exclamation mark
GHS07

signalword

Warning

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Los clientes también vieron

Slide 1 of 1

1 of 1

Proadifen hydrochloride analytical standard, ≥95%

Supelco

P1061

Proadifen hydrochloride

Seth Kwabena Amponsah et al.
Evidence-based complementary and alternative medicine : eCAM, 2020, 7956493-7956493 (2020-07-28)
There is considerable evidence that many patients concurrently administer dietary supplements with conventional drugs, creating a risk for potential drug-supplement interaction. The aim of this study was to determine the effect of Cellgevity® supplement on selected rat liver cytochrome P450
Shosaku Kashiwada et al.
Comparative biochemistry and physiology. Toxicology & pharmacology : CBP, 141(4), 338-348 (2005-08-23)
Phylogenic analysis of the teleost genomic lineages has demonstrated the precedent for multiple genome duplications. Among many of the genes duplicated, cytochrome P450 genes have undergone independent diversification, which can be traced to a single ancestral gene. In teleosts, cytochrome
Lana X Garmire et al.
Pharmaceutical research, 24(12), 2171-2186 (2007-08-19)
Validate and exemplify a discrete, componentized, in silico, transwell device (ISTD) capable of mimicking the in vitro passive transport properties of compounds through cell monolayers. Verify its use for studying drug-drug interactions. We used the synthetic modeling method. Specialized software
L E Beebe et al.
Biochemical pharmacology, 52(10), 1507-1513 (1996-11-22)
Suicide inhibitors of cytochrome P450 families are excellent tools to predict which isoforms mediate the metabolism/activation of a variety of chemical agents. We compared the inhibitory effects of several arylalkynes on mouse cytochromes P450 with published data for the rat
R R Meehan et al.
The Biochemical journal, 254(3), 789-797 (1988-09-15)
Cytochrome P-450s are a superfamily of haem-containing proteins involved in the metabolism of foreign compounds, as well as a variety of endogenous molecules. The hepatic levels and function of this diverse group of enzymes are determined by both constitutive and
Ver todos los artículos relacionados

Artículos

Phase I Drug Metabolism

Phase I biotransformation reactions increase drug compound polarity, mainly occurring in hepatic circulation.

Phase I Drug Metabolism

Phase I biotransformation reactions increase drug compound polarity, mainly occurring in hepatic circulation.

Phase I Drug Metabolism

Phase I biotransformation reactions increase drug compound polarity, mainly occurring in hepatic circulation.

Phase I Drug Metabolism

Phase I biotransformation reactions increase drug compound polarity, mainly occurring in hepatic circulation.

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico